Arcus Biosciences Inc
NYSE:RCUS

Watchlist Manager
Arcus Biosciences Inc Logo
Arcus Biosciences Inc
NYSE:RCUS
Watchlist
Price: 16.77 USD -5.52% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Arcus Biosciences Inc?
Write Note

Wall Street
Price Targets

RCUS Price Targets Summary
Arcus Biosciences Inc

Wall Street analysts forecast RCUS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RCUS is 32.92 USD with a low forecast of 20.2 USD and a high forecast of 48.3 USD.

Lowest
Price Target
20.2 USD
20% Upside
Average
Price Target
32.92 USD
96% Upside
Highest
Price Target
48.3 USD
188% Upside

RCUS Last Price Targets
Arcus Biosciences Inc

The latest public price target was made on Oct 24, 2024 by Yigal Nochomovitz from Citigroup , who expects RCUS stock to rise by 174% over the next 12 months. You can read more about this price target by viewing the article on TheFly.

Analyst Price Target Date Article
Yigal Nochomovitz
Citigroup
46 USD
Upside 174%
2 weeks ago
Oct 24, 2024
Arcus Biosciences price target raised to $46 from $38 at Citi
TheFly
Emily Bodnar
H.C. Wainwright
20 USD
Upside 19%
3 weeks ago
Oct 21, 2024
H.C. Wainwright Starts Arcus Biosciences (RCUS) at Neutral
StreetInsider
Eva Fortea Verdejo
Wells Fargo
29 USD
Upside 73%
1 month ago
Oct 8, 2024
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Benzinga
Judah Frommer
Morgan Stanley
35 USD
Upside 109%
1 month ago
Oct 8, 2024
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Benzinga
Jason Zemansky
Bank of America Securities
23 USD
Upside 37%
3 months ago
Aug 9, 2024
Arcus Biosciences (RCUS) PT Lowered to $23 at BofA Securities
StreetInsider
Peter Lawson
Barclays
25 USD
Upside 49%
4 months ago
Jul 8, 2024
Arcus Biosciences (RCUS) PT Lowered to $25 at Barclays
StreetInsider
Asthika Goonewardene
Truist Financial
44 USD
Upside 162%
4 months ago
Jun 24, 2024
Arcus Biosciences (RCUS) PT Lowered to $44 at Truist Securities
StreetInsider
Peter Lawson
Barclays
35 USD
Upside 109%
5 months ago
Jun 4, 2024
Barclays Reiterates Overweight Rating on Arcus Biosciences (RCUS)
StreetInsider
Show More Price Targets
Show Less Price Targets
Yigal Nochomovitz
Citigroup
Price Target 46 USD
Upside/Downside 174%
View Source
Emily Bodnar
H.C. Wainwright
Price Target 20 USD
Upside/Downside 19%
View Source
Eva Fortea Verdejo
Wells Fargo
Price Target 29 USD
Upside/Downside 73%
View Source
Judah Frommer
Morgan Stanley
Price Target 35 USD
Upside/Downside 109%
View Source
Jason Zemansky
Bank of America Securities
Price Target 23 USD
Upside/Downside 37%
View Source
Peter Lawson
Barclays
Price Target 25 USD
Upside/Downside 49%
View Source
Asthika Goonewardene
Truist Financial
Price Target 44 USD
Upside/Downside 162%
View Source
Peter Lawson
Barclays
Price Target 35 USD
Upside/Downside 109%
View Source
Show More Price Targets
Show Less Price Targets
Arcus Biosciences Inc Competitors:
Price Targets
KRON
Kronos Bio Inc
357% Upside
4599
StemRIM Inc
95% Upside
EDIT
Editas Medicine Inc
347% Upside
STTK
Shattuck Labs Inc
62% Upside
KOD
Kodiak Sciences Inc
45% Downside
BEAM
Beam Therapeutics Inc
78% Upside
VCYT
Veracyte Inc
1% Downside
ABOS
Acumen Pharmaceuticals Inc
327% Upside

Revenue
Forecast

Revenue Estimate
Arcus Biosciences Inc

For the last 6 years the compound annual growth rate for Arcus Biosciences Inc's revenue is 109%. The projected CAGR for the next 3 years is 25%.

109%
Past Growth
25%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Arcus Biosciences Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Arcus Biosciences Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RCUS's stock price target?
Price Target
32.92 USD

According to Wall Street analysts, the average 1-year price target for RCUS is 32.92 USD with a low forecast of 20.2 USD and a high forecast of 48.3 USD.

What is Arcus Biosciences Inc's Revenue forecast?
Projected CAGR
25%

For the last 6 years the compound annual growth rate for Arcus Biosciences Inc's revenue is 109%. The projected CAGR for the next 3 years is 25%.

Back to Top